Summary & Overview
CPT 0472U: Early Sjögren’s Syndrome ELISA Antibody Profile
CPT code 0472U designates a Proprietary Laboratory Analyses (PLA) test marketed by Immco Diagnostics Inc. for the Early Sjögren’s Syndrome Profile. The ELISA-based panel detects IgG, IgM, and IgA antibodies to CA VI, PSP, and SP1 in blood and reports semiqualitative positive/negative results that serve as predictive evidence of early Sjögren’s syndrome. Nationally, PLA codes like 0472U matter because they identify manufacturer-specific assays and affect how payers evaluate coverage, coding specificity, and claims adjudication for niche diagnostic tests.
Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise description of the test and its clinical context, an overview of typical sites of service and service type, and a summary of common billing modifiers and administrative details when available. The publication provides benchmarking context and policy-relevant notes for payers and provider billing teams, along with clinical background on the role of these antibody markers in identifying early-stage Sjögren’s syndrome. Data not available in the input is identified as such in relevant sections.
Billing Code Overview
CPT code 0472U is a Proprietary Laboratory Analyses (PLA) code that applies exclusively to the Early Sjögren’s Syndrome Profile developed by Immco Diagnostics Inc. The test uses enzyme–linked immunosorbent assay (ELISA) to measure immunoglobulin G (IgG), immunoglobulin M (IgM), and immunoglobulin A (IgA) antibodies directed against carbonic anhydrase VI (CA VI), parotid specific/secretory protein (PSP), and salivary protein (SP1). Results are reported semiqualitatively as positive or negative for the presence of these antibodies.
Service type: Laboratory testing using ELISA-based serologic antibody panel for early detection of Sjögren’s syndrome.
Typical site of service: Clinical laboratory processing a blood specimen; specimen collection may occur in outpatient clinics, physician offices, or phlebotomy centers.
Clinical & Coding Specifications
Clinical Context
A 42-year-old woman presents to a rheumatology clinic with a 9-month history of progressive dry mouth and dry eyes, intermittent parotid gland swelling, and new onset fatigue. The treating rheumatologist documents suspicion for early Sjögren’s syndrome based on symptoms and physical exam. A blood sample is collected in the clinic and sent to Immco Diagnostics Inc. for the Early Sjögren’s Syndrome Profile. The laboratory performs the proprietary enzyme–linked immunosorbent assay (ELISA) that measures IgG, IgM, and IgA antibodies to carbonic anhydrase VI (CA VI), parotid specific/secretory protein (PSP), and salivary protein (SP1). The test yields semiqualitative positive/negative results that the laboratory reports to the ordering provider as predictive evidence of early Sjögren’s syndrome. Typical workflow steps include: ordering the PLA test from the electronic health record, phlebotomy at the ambulatory clinic, specimen handling and shipment to the performing specialty lab, laboratory testing using the proprietary ELISA, and laboratory report review by the rheumatologist to guide further diagnostic evaluation such as ocular staining, salivary flow testing, or consideration of salivary gland biopsy.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | Default or unmodified service | Use when no special modifier applies; report the PLA code without additional modifier when service is routine. |
22 | Increased procedural services | Use when the laboratory or ordering provider documents significantly greater complexity or work beyond the usual for the test (rare for standardized PLA testing). |
52 | Reduced services | Use when the test is partially performed or a component of the assay cannot be completed and a reduced service is reported. |
53 | Discontinued procedure | Use if specimen collection or testing is started but discontinued for unavoidable clinical reasons prior to completion. |
90 | Reference (outside) laboratory | Use when the performing laboratory is not the billing entity and testing is sent to an outside reference lab (common when outpatient clinic sends to Immco Diagnostics Inc.). |
26 | Professional component | Use if billing only for professional component (interpretation) when separate from technical component (rare for PLA but applicable if split billing occurs). |
TC | Technical component | Use when billing only the technical component of the test (specimen processing and laboratory performance) and the professional component is billed separately. |
QW | CLIA-waived test | Not typically applicable to this PLA; include only when a waived-status test is being reported (generally not used for proprietary ELISA PLA). |
59 | Distinct procedural service | Use when reporting a distinct lab procedure performed on the same date that is unrelated to the PLA test and requires separate billing. |
XE | Separate encounter | Use when the lab service was provided during a separate encounter distinct from other services billed the same date. |
| Taxonomy Code | Specialty | Notes |
|---|---|---|
| 207RH0000X | Rheumatology | Rheumatologists commonly order the Early Sjögren’s Syndrome Profile when evaluating suspected Sjögren’s syndrome. |
| 2080P0206X | Clinical Pathology | Pathologists or clinical laboratory directors oversee testing quality and interpretation protocols for specialty labs performing PLA testing. |
| 364S00000X | Laboratory Medicine | Laboratory medicine specialists direct performance and validation of proprietary ELISA assays in reference laboratories. |
| 261QM0800X | Otolaryngology | Otolaryngologists (ENT) may be involved in management of salivary gland disorders and may order or interpret results in certain clinical pathways. |
Related Diagnoses
| ICD-10 Code | Description | Clinical Relevance |
|---|---|---|
M35.00 | Sicca syndrome, unspecified | Directly related to dry eyes and dry mouth symptoms evaluated with the Early Sjögren’s Syndrome Profile. |
M35.01 | Secondary Sjögren syndrome | Used when Sjögren’s features occur in the setting of another autoimmune disease such as rheumatoid arthritis. |
M35.02 | Primary Sjögren syndrome with organ involvement | Applied when serologic testing and clinical findings support primary Sjögren’s syndrome with systemic involvement. |
H04.123 | Dry eye syndrome, bilateral | Symptom code for keratoconjunctivitis sicca commonly evaluated alongside Sjögren’s testing. |
K11.7 | Disturbances of salivary secretion | Clinical code for xerostomia and salivary gland dysfunction that prompt ordering of the PLA test. |
Related CPT Codes
| CPT Code | Description | Relationship to This Procedure |
|---|---|---|
80101 | Therapeutic drug assay; immunoassay qualitative (e.g., drug of abuse) | Represents general immunoassay methodology; not specific to Sjögren’s PLA but conceptually related laboratory technique. |
80053 | Comprehensive metabolic panel; includes multiple chemistry tests | Often ordered concurrently to evaluate baseline organ function prior to autoimmune workup and to exclude metabolic causes of symptoms. |
83036 | Hemoglobin; glycosylated (A1c) | Frequently part of general laboratory evaluation in patients with systemic symptoms to assess for diabetes, which can contribute to sicca symptoms. |
86580 | Skin test and intermediate antigen test; e.g., miscellaneous | Represents ancillary immunologic testing codes sometimes used in immunology panels; used here as an example of related immunologic testing workflows. |
88305 | Surgical pathology, gross and microscopic examination | If salivary gland biopsy is performed following positive PLA results, this code represents pathology processing and interpretation. |